Amplifon, the world’s largest hearing aid retailer, announced on March 31 a $2 billion acquisition of GN Hearing, known for brands such as ReSound, Beltone and Jabra Enhance.
The deal marks a significant change for Amplifon, which has historically focused on retail operations and relied on major manufacturers like Sonova, Demant and GN for its products. With this move, Amplifon shifts towards becoming a fully vertically integrated provider that includes research and development, manufacturing, and clinical delivery.
Vertical integration is common in healthcare but is considered an important evolution within audiology. By bringing manufacturing in-house, Amplifon will have more control over product development timelines and pricing structures. This could lead to faster innovation and potentially more streamlined care pathways where the company already has a strong retail presence.
The acquisition comes as something of a surprise to industry observers who had expected possible consolidation between manufacturers such as GN and Demant. Instead, this transaction reflects a broader trend across healthcare industries: the merging of retail operations with production capabilities.
For patients worldwide, this may result in improved innovation and service integration. However, there are concerns about increased competition pressures on independent clinics as large corporate providers grow larger. In the UK specifically, immediate effects may be limited due to Amplifon's recent market exit; globally though, the deal is expected to reshape competition within audiology.
